3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lung Neoplasms
1
Hematologic Diseases
1
Fatigue
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Bone Neoplasms
1
Bone Marrow Diseases
1
Interventions
fludarabine
25
Cyclophosphamide
20
Azacitidine
20
venetoclax
18
Specimen Handling
18
fludarabine phosphate
17
Mycophenolic Acid
14
Melphalan
14
Busulfan
14
Biopsy
14
Whole-Body Irradiation
13
Tacrolimus
12
Cytarabine
12
Granulocyte Colony-Stimulating Factor
10
decitabine and cedazuridine drug combination
9
Decitabine
9
Stem Cell Transplantation
8
Sirolimus
8
Injections
8
Filgrastim
8
Cyclosporine
8
Peripheral Blood Stem Cell Transplantation
7
Thiotepa
6
ruxolitinib
5
X-Rays
5
Idarubicin
5
Magnetic Resonance Spectroscopy
4
Cladribine
4
CPX-351
4
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
Quality of Life
×
90 days
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled